NASDAQ$IRD
Opus Genetics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Ocuphire Pharma reported financial results for the first quarter of 2022 and provided a corporate update.
Ocuphire Pharma reported a net loss of $6.6 million, or $0.35 per share, for Q1 2022. As of March 31, 2022, the company's cash and cash equivalents totaled $19.2 million, expected to fund operations into Q2 2023.
- Nyxol posted 5 positive clinical data readouts including presbyopia in the last 12 months.
- Successfully enrolled 4 late-stage trials for Nyxol and APX3330 in the first quarter.
- NDA filing is on track for late 2022 for potential 2023 approval of Nyxol as the only dilation reversal drop.
- Data is expected in 2H22 from Phase 2b trial of oral APX3330 for Diabetic Retinopathy
Headline financials
Revenue & EPS history
Ocuphire · Revenue · Quarterly
$0
Revenue by segment
Ocuphire · $100K total across 1 segment · Q2 2021
- Collaboration Revenue$100K—100.0%
Forward guidance
Ocuphire is planning for an NDA filing with the FDA for Nyxol in RM indication in late 2022, with potential launch in 2H 2023. They plan to initiate VEGA Phase 3 program in mid-2022, and report top-line results from the Nyxol Phase 3 LYNX-1 trial in Q2 2022 and APX3330 Phase 2b ZETA-1 trial in 2H 2022.
Tailwinds
- Planned New Drug Application (NDA) with the FDA for Nyxol in RM indication in late 2022
- Potential launch as first dilation reversal drop in 2H 2023
- Initiate VEGA Phase 3 program in mid-2022 investigating Nyxol alone and Nyxol with 0.4% low-dose pilocarpine (LDP) as adjunctive therapy
- File an NDA in 2023 if VEGA Phase 3 program is successful
- Report top-line results from the Nyxol Phase 3 LYNX-1 trial in 2Q 2022
Headwinds
- Success and timing of planned regulatory filings (including NDA filings)
- Potential increase in the identification of DR patients
- Future clinical trials
- Commercialization of Ocuphire’s product candidates
- Reliance on current expectations and assumptions that may never materialize or may prove to be incorrect
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
-3.6%
Avg return
Earnings day
-3.8%
Avg return
5 days after
-3.1%
Avg return
30 days after
42%
14 / 33 earnings
Positive
+16.7%
Q1 2017
Best reaction
-47.3%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -6.1% | — | |
| Q4 2025 | +1.7% | +5.5% | +15.3% | |
| Q3 2025 | -3.1% | -11.7% | +19.8% | |
| Q2 2025 | +7.4% | +0.9% | +25.5% | |
| Q1 2025 | +7.5% | +4.2% | +2.1% | |
| Q3 2024 | -7.7% | -9.4% | -5.1% | |
| Q2 2024 | -24.7% | -19.9% | -24.1% | |
| Q1 2024 | -14.3% | -11.7% | -13.8% | |
| Q4 2023 | -12.2% | -13.9% | -19.7% | |
| Q3 2023 | +13.4% | +3.5% | -4.9% | |
| Q2 2023 | +0.5% | +0.7% | -3.1% | |
| Q1 2023 | -18.9% | -28.0% | -36.0% | |
| Q4 2022 | +4.2% | +44.2% | +42.5% | |
| Q3 2022 | -2.8% | +13.1% | +52.3% | |
| Q2 2022 | -9.7% | -6.1% | -14.3% | |
| Q1 2022 | +8.5% | +6.5% | +5.5% | |
| Q4 2021 | +11.1% | -9.9% | -35.9% | |
| Q3 2021 | -0.3% | -10.9% | -5.6% | |
| Q2 2021 | -8.5% | -14.7% | -0.6% | |
| Q1 2021 | -7.8% | -5.9% | +17.4% | |
| Q4 2020 | -12.7% | -7.8% | -34.7% | |
| Q3 2020 | +1.4% | -10.8% | -22.4% | |
| Q2 2020 | -1.6% | +1.2% | -25.9% | |
| Q1 2020 | -16.4% | -2.7% | +3.8% | |
| Q3 2019 | -5.9% | -9.3% | -11.2% | |
| Q2 2019 | -47.3% | -49.3% | -54.8% | |
| Q1 2019 | -10.4% | -11.0% | -10.3% | |
| Q2 2018 | +2.7% | +5.4% | +17.0% | |
| Q4 2018 | -2.9% | -3.5% | -4.7% | |
| Q3 2017 | +4.9% | +6.5% | +15.7% | |
| Q2 2017 | +5.9% | -1.6% | +26.5% | |
| Q1 2017 | +16.7% | +29.2% | -10.4% | |
| Q2 2016 | +0.0% | -3.7% | -3.7% | |
| Q1 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro